- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Vehicle
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 11
- States / cities
- Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 408
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- Questionnaires
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Travoprost ophthalmic solution, 0.0008%, Travoprost ophthalmic solution, 0.001%, Travoprost ophthalmic solution, 0.0012%, TRAVATAN, Vehicle
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Open-angle Glaucoma or Ocular Hypertension
- Interventions
- DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
- Drug · Other
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Xalacom, Xalatan, Timolol
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more
- Conditions
- Glaucoma, Cataract
- Interventions
- Cornea/Anterior Segment OCT CASIA2, Optovue RTVue XR Avanti
- Device
- Lead sponsor
- Tomey Corporation
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- OTX-TIC
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Petaluma, California • Torrance, California • Roswell, Georgia + 2 more
- Conditions
- Glaucoma
- Interventions
- AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 18
- States / cities
- Inglewood, California • Petaluma, California • Poway, California + 15 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Wenatchee, Washington
- Conditions
- Glaucoma
- Interventions
- MEMS cap
- Device
- Lead sponsor
- Robin, Alan L., M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Glaucoma, Stent Migration, Stent Dislodgement, Intraocular Pressure
- Interventions
- Cataract plus Microstent surgery
- Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
- Interventions
- Direct Selective laser Trabeculoplasty
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Glaucoma, Adherence, Patient
- Interventions
- monitoring of adherence with medication
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 92 participants
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Open-Angle Glaucoma
- Interventions
- AlloSpan Canal Platform Bio-Reinforced Canaloplasty
- Procedure
- Lead sponsor
- Iantrek, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 9
- States / cities
- Chico, California • Petaluma, California • Alexandria, Minnesota + 6 more
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 30
- States / cities
- Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
- Conditions
- Glaucoma
- Interventions
- Glaucoma Diagnosis, Name: Neucodia
- Device
- Lead sponsor
- Synabridge Corporation
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Raritan, New Jersey + 2 more
- Conditions
- Glaucoma, Open-Angle [C11.525.381.407]
- Interventions
- Open angle glaucoma - iDropper device
- Device
- Lead sponsor
- Care Team Solutions
- Industry
- Eligibility
- 21 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Interventions
- Hydrus Microstent, Ophthalmic surgery
- Device · Procedure
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Bentonville, Arkansas • Zephyrhills, Florida • Fraser, Michigan + 2 more
- Conditions
- Glaucoma, Retinal Disease, Corneal Disease
- Interventions
- Not listed
- Lead sponsor
- Nidek Co. LTD.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Glaucoma
- Interventions
- Travoprost 0.004%/timolol maleate 0.5% fixed combination
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
- Interventions
- Arm 1
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- RKI983A, Latanoprost
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 29
- States / cities
- Artesia, California • Inglewood, California • La Jolla, California + 25 more